Trial Profile
Aditive effects of omega-3 polyunsaturated fatty acids and pioglitazone in the treatment of type 2 diabetes mellitus.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Mar 2016
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Eicosapentaenoic acid/docosahexaenoic acid
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms MEPIO
- 19 Jul 2011 New trial record